Ingevity Corp updated its full year guidance (reaffirmed).
“Reaffirms full year guidance, adjusted for sale of Road Markings”
Ingevity Corp — fact timeline
Source-grounded facts extracted from Ingevity Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Ingevity Corp reported three months ended March 31, 2026 results: revenue $258.0 million, net income $23.4 million, EPS $0.65.
“Ingevity reports first quarter 2026 financial results First Quarter 2026 Results & Recent Highlights: • Net sales of $258.0 million increased 4% from prior year • Net income from continuing operations of $23.4 million and $0.65 per diluted share compared to $29.1 million and $0.79 in the prior year”
Ingevity Corp amended revolving credit of decreased from $1 billion to $750 million with JPMorgan Chase Bank, N.A. at term benchmark rate (subject to 0.00% floor) plus applicable margin of 1.00% to maturing five years after the Closing Date (March 26, 2026).
“The Amendment amends and restates the Existing Credit Agreement to, among other things, (a) extend the maturity date of the Company’s revolving credit facility to the date that is five years after the Closing Date, (b) decrease the aggregate amount of the commitments thereunder from $1 billion to $750 million and (c) effect certain other amendments.”
Ingevity Corp entered into Second Amendment and Restatement Agreement with JPMorgan Chase Bank, N.A., as administrative agent valued at $750 million (effective 2026-03-26).
“On March 26, 2026 (the “ Closing Date ”), Ingevity Corporation (the “ Company ”), Ingevity Holdings SRL (“ Holdings ”), Ingevity UK Ltd (the “ UK Borrower ”), the other loan parties party thereto, the lenders party thereto, the issuing banks party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “ Administrative Agent ”), collateral agent and swingline lender, entered into that certain Second Amendment and Restatement Agreement (the “ Amendment ”), which amends and restates the Amended and Restated Credit Agreement, dated as of June 23, 2022”
Ingevity Corp amended Amendment with the Parties (effective 2026-01-01).
“In connection with the Closing, on January 1, 2026, the Parties entered into the Amendment, which, among other things, modified the scope of assets being transferred pursuant to the Original Purchase Agreement by excluding non-lignin dispersant products sold to existing customers for agricultural chemical applications.”
Ingevity Corp completed a disposition involving Mainstream Pine Products, LLC (closed 2026-01-01).
“On January 1, 2026, Ingevity Corporation, a Delaware corporation (“Ingevity”), completed the transaction (the “Transaction”) previously disclosed in its Current Report on Form 8-K filed by Ingevity with the Securities and Exchange Commission (“SEC”) on September 4, 2025 (the “Previous Form 8-K”).”
Bruce D. Hoechner was elected as Chair of the Board at Ingevity Corp.
“the election of Mr. Bruce D. Hoechner as Chair of the Board”
F. David Segal was elected as Director at Ingevity Corp.
“the election of Mr. David H. Li and Mr. F. David Segal to fill the vacancies created by the expansion of the Board”
David H. Li was elected as Director at Ingevity Corp.
“the election of Mr. David H. Li and Mr. F. David Segal to fill the vacancies created by the expansion of the Board”
Luis Fernandez-Moreno departed as interim President and Chief Executive Officer at Ingevity Corp.
“In connection with Mr. Li’s appointment, Luis Fernandez-Moreno will step down as interim President and Chief Executive Officer of Ingevity as of the Effective Date.”
David H. Li was appointed as President and Chief Executive Officer at Ingevity Corp.
“On March 10, 2025, Ingevity Corporation (“Ingevity”) announced that its Board of Directors (the “Board”) has appointed David H. Li as President and Chief Executive Officer of Ingevity, effective April 7, 2025”
Luis Fernandez-Moreno was appointed as interim President and Chief Executive Officer at Ingevity Corp.
“the Board has appointed Luis Fernandez-Moreno as the interim President and Chief Executive Officer of the Company”
John C. Fortson resigned as Member of the Board at Ingevity Corp.
“He succeeds John C. Fortson, who departed as President and Chief Executive Officer and has resigned as a member of the Board, effective as of October 2, 2024.”
John C. Fortson departed as President and Chief Executive Officer at Ingevity Corp.
“He succeeds John C. Fortson, who departed as President and Chief Executive Officer and has resigned as a member of the Board, effective as of October 2, 2024.”
Ryan C. Fisher was appointed as Senior Vice President, General Counsel and Secretary at Ingevity Corp.
“Ryan C. Fisher, previously the Company’s Vice President, Deputy General Counsel and Chief Compliance Officer, has been appointed Senior Vice President, General Counsel and Secretary of the Company.”
Stacy L. Cozad resigned as Executive Vice President, General Counsel and Secretary at Ingevity Corp.
“On June 26, 2024, Stacy L. Cozad notified Ingevity Corporation (the “Company”) of her decision to resign as Executive Vice President, General Counsel and Secretary of the Company, which resignation took effect as of such date.”
Ingevity Corp reported the three months ended March 31, 2024 results: revenue $340.1 million, net income Net loss of $56.0 million and diluted loss per share (EPS) of $1.54; adjusted earnings of $19.1 million and diluted adju. Guidance reaffirmed.
“John E. Nypaver, Jr. 843-740-2002 investors@ingevity.com Ingevity reports first quarter 2024 financial results HIGHLIGHTS : (comparisons versus prior year period) • Net sales of $340.1 million, down 13% primarily as a result of the repositioning of Performance Chemicals • Net loss of $56.0 million and diluted loss per share (EPS) of $1.54; adjusted earnings of $19.1”
Ingevity Corp shareholders approved Approval of amendment to the Company’s Certificate of Incorporation to provide for the exculpation of certain officers from liability in limited circumstances at the 2024-04-23 meeting.
“Approval of amendment to the Company’s Certificate of Incorporation to provide for the exculpation of certain officers from liability in limited circumstances.”
Ingevity Corp shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal 2024 at the 2024-04-23 meeting.
“Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal 2024.”
Ingevity Corp shareholders approved Approval, on a non-binding, advisory basis, of the compensation of our named executive officers at the 2024-04-23 meeting.
“Approval, on a non-binding, advisory basis, of the compensation of our named executive officers.”
Ingevity Corp shareholders approved Election of nine director nominees at the 2024-04-23 meeting.
“Election of the nine (9) director nominees listed below, each for a one-year term or until his or her successor is duly elected and qualified:”
William J. Slocum resigned as Director at Ingevity Corp.
“On March 12, 2024, William J. Slocum informed the Nominating & Governance Committee of the Board of Directors (the “Board”) of Ingevity Corporation (the “Company”) of his resignation from the Board effective as of March 13, 2024 at 5:00 p.m.”
Ingevity Corp reported the twelve months ended December 31, 2023 results: revenue $1.69 billion, net income Net loss of $5.4 million and diluted loss per share of $0.15, EPS diluted loss per share of $0.15. Guidance initiated.
“assets to be shut down during the first half of the year • Implemented significant cost savings actions Full Year (comparisons versus prior year period): • Net sales of $1.69 billion increased 1.4% • Net loss of $5.4 million and diluted loss per share of $0.15, including restructuring charges of $145.3 million; adjusted earnings of $144.7 million and diluted”
Ingevity Corp reported the three months ended December 31, 2023 results: revenue $371.7 million, net income Net loss of $116.8 million and diluted loss per share of $3.23, EPS diluted loss per share of $3.23. Guidance initiated.
“843-740-2002 investors@ingevity.com Ingevity reports fourth quarter and full year 2023 financial results Fourth Quarter (comparisons versus prior year period): • Net sales of $371.7 million decreased 3.1% • Net loss of $116.8 million and diluted loss per share of $3.23, including restructuring charges of $107.5 million; adjusted earnings of $7.8 million and diluted”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.